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Abstract
The overgrowth of synovial tissues is critical in the pathogenesis
of rheumatoid arthritis (RA). The expression of Synoviolin (SYN),
an E3 ubiquitin ligase, is upregulated in arthritic synovial
fibroblasts and is involved in the overgrowth of synovial cells
during RA. However, the molecular mechanisms involved in the
elevated SYN expression are not known. Here, we found that
SYN expression is elevated in the synovial fibroblasts from mice
with collagen-induced arthritis (CIA). The proinflammatory
cytokines interleukin (IL)-1β and tumor necrosis factor-α (TNF-
α) induce SYN expression in mouse synovial fibroblasts.
Cultivation of mouse synovial fibroblasts with IL-1β activates
mitogen-activated protein kinases, including extra-cellular
signal-regulated kinase (Erk), JNK (c-Jun N-terminal kinase), and
p38, while only Erk-specific inhibitor blocks IL-1β-induced SYN
expression. Expression of transcription factor ETS1 further
enhances IL-1β-induced SYN expression. The dominant
negative ETS1 mutant lacking the transcription activation
domain inhibits SYN expression in a dose-dependent manner.
The activation of both Erk1/2 and ETS1 is increased in the CIA
synovial fibroblasts. Inhibition of Erk activation reduces ETS1
phosphorylation and SYN expression. Our data indicate that the
proinflammatory cytokines IL-1β and TNF-α induce the
overgrowth of synovial cells by upregulating SYN expression via
the Erk1/-ETS1 pathway. These molecules or pathways could
therefore be potential targets for the treatment of RA.
Introduction
Rheumatoid arthritis (RA) is a chronic debilitating disease of
the joints characterized by leukocyte infiltration, hyperprolifer-
ation of synovial cells, and bone destruction. Hyperproliferative
synovial fibroblasts play a critical role in the pathogenesis of
RA by the following mechanisms: They directly invade bone
and cartilage, produce proinflammatory cytokines such as
tumor necrosis factor-α (TNF-α) and interleukin (IL)-1β [1],
destroy cartilage through the production of metalloproteinase
[2], and produce the receptor of nuclear factor-kappa B (NF-
κB) ligand, which augments osteoclast activity for bone
destruction [3-5]. Therefore, inhibition of the proliferative and/
or invasive capacities of synovial fibroblasts should have pro-
tective effects against joint destruction.
Synoviolin (SYN), which is also called Hrd1 (3-hydroxy-3-
methylglutaryl reductase degradation), was identified by
Hampton and co-workers [6] as an E3 ubiquitin ligase in yeast.
SYN is a multispanning membrane protein with its C-terminal
RING (really interesting new gene) finger domain located in
the cytoplasm [6,7]. It has been reported that human SYN is
involved in the elimination of two endoplasmic reticulum (ER)-
associated degradation substrates, T-cell receptor-α and
CD3-δ, via its E3 ubiquitin ligase activity [8]. Ubiquitination is
a process that covalently conjugates ubiquitin to the target
protein for degradation. This process requires a cascade of
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three enzymes, E1, E2, and E3. SYN predominantly uses the
ubiquitin-conjugation enzyme 7p (Ubc7p) as an E2 but also
cooperates with Ubc6p and Ubc1p in ER-associated degra-
dation [9]. SYN is also required for the mouse embryo devel-
opment because the gene knockout mice die in utero at
approximately embryonic day 13.5 [10].
By means of immunoscreening with an anti-rheumatoid syno-
vial cell antibody, SYN was identified and cloned as a rheuma-
toid regulator. Expression of SYN is highly associated with the
development of RA. Mice with overexpressed SYN (SYN
transgenic mice) develop spontaneous arthropathy. On the
other hand, mice with reduced SYN (SYN+/- mice) are resist-
ant to collagen-induced arthritis (CIA). Further in vitro study
revealed that, through its anti-apoptotic activities, SYN trig-
gers the outgrowth of synovial fibroblasts [11,12]. Therefore,
inhibition of the expression of SYN has potential therapeutic
benefit in the prevention or treatment of RA. However, the
molecular mechanisms involved in overexpression of SYN dur-
ing RA remain unknown.
In this study, we found that the proinflammatory cytokines, par-
ticularly IL-1β, upregulate SYN expression at the transcrip-
tional level. The extra-cellular signal-regulated kinase (Erk)-
ETS1 signal pathway is involved in IL-1β-induced SYN
expression.
Materials and methods
Reagents, antibodies, and plasmids
All the mitogen-activated protein kinase (MAPK) inhibitors
used in this study, including the Erk activation inhibitor,
PD98059 [13], the c-Jun N-terminal kinase (JNK) inhibitor,
SP600125 [14], p38 inhibitor, SB202190 [15], and the NF-
κB inhibitor, SN50 [16], were purchased from Calbiochem
(San Diego, CA, USA). Antibodies against JNK1, Erk, and p38
were purchased from Promega Corporation (Madison, WI,
USA). Murine IL-1β, IL-6, and TNF-α were obtained from BD
Pharmingen (San Diego, CA, USA). Anti-actin monoclonal
antibody was purchased from Santa Cruz Biotechnology, Inc.
(Santa Cruz, CA, USA), and anti-ETS1 was obtained from
EMD Biosciences, Inc. (San Diego, CA, USA). Antibodies
against Erk, c-Jun, and ATF2, as well as their phosphorylated
forms, were purchased from Promega Corporation. Anti-SYN
polyclonal antibody was generated in our laboratory by immu-
nization of mice with glutathione S-transferase (GST)-fusion
protein of the C-terminal 152 amino acids of SYN. ETS1 full-
length cDNA was purchased from American Type Culture Col-
lection (ATCC) (Manassas, VA, USA) (ATCC no. 5844553).
The C-terminal DNA binding domain of ETS1 was amplified by
polymerase chain reaction (PCR) and subcloned into pEF4 his
expression vectors digested by KpnI and Not1.
Mice and CIA
DBA1 mice (The Jackson Laboratory, Bar Harbor, ME, USA)
were bred and maintained in accordance with the guidelines
of the institutional animal care and use committee (IACUC),
and all the experimental procedures were approved by the
IACUC of the University of Missouri (Columbia, MO, USA).
Native bovine collagen II (Worthington Biochemical Corpora-
tion, Lakewood, NJ, USA) was emulsified with an equal volume
of complete Freund's Adjuvant (CFA). Disease was induced
by intradermal injection of DBA1 mice with 50 μl of emulsion
containing 100 μg of collagen in CFA. On day 21, the mice
were boosted by intradermal injection with 100 μg of collagen
in incomplete Freund's Adjuvant. Clinical arthritis was
assessed by the following scoring system: grade 0, no swell-
ing; grade 1, mild but definite redness and swelling of the
ankle or wrist or digits; grade 2, moderate redness and swell-
ing of ankle and wrist; grade 3, severe redness and swelling of
entire paw, including digits; and grade 4, maximally inflamed
limb with involvement of multiple joints. Each limb was graded,
giving a maximum possible score of 16 per mouse. Approxi-
mately 80% of DBA1 mice developed arthritis 40 days after
the first injection with collagen (supplemental Figure 1a in
Additional file 1), and most of these mice developed severe
arthritis with an average score of 12 (supplemental Figure 1b
in Additional file 1).
Isolation of synovial fibroblasts
Synovial tissues were obtained from DBA1 mice as described
previously [17]. These joint tissues were minced and incu-
bated with 1 mg/ml of collagenase (Worthington Biochemical
Corporation) in serum-free Dulbecco's modified Eagle's
medium (DMEM) for 3 hours at 37°C, filtered through a nylon
mesh, extensively washed, and cultured in DMEM supple-
mented with 10% fetal calf serum (Fisher Scientific Co., Pitts-
burgh, PA, USA), 100 U penicillin, 100 μg/ml streptomycin,
and 50 mg/ml L-glutamine in a humidified atmosphere contain-
ing 5% CO2. After overnight culture, we removed the nonad-
herent cells, trypsinized the adherent cells split at a ratio of
1:3, and cultured them in medium. Synoviocytes were used
from passages 3 to 9 in these experiments, during which they
consisted of a homogeneous population of synovial fibroblasts
monitored by flow cytometry with less than 1% of CD11b,
phagocytic, and Fc receptor II-positive cells.
SDS-PAGE and Western blotting
We analyzed the expression of SYN by SDS-PAGE and West-
ern blotting as described previously [18]. Synovial fibroblasts
were collected from culture dishes and lysed with Nonidet P-
40 (NP-40) lysis buffer (20 mM Tris-HCl with pH 7.5, 150 mM
NaCl, 1% NP-40, and protease inhibitor cocktail was added
freshly) and boiled in 20 μl of Laemmli's buffer (50 mM Tris-
HCl, pH 6.8, 30% glycerol, 4% SDS, and 1% β-mercaptoeth-
anol). Samples were subjected to 8% or 10% analysis by
SDS-PAGE and electrotransferred onto polyvinylidene difluo-
ride membranes (Millipore, Billerica, MA, USA). Membranes
were probed with the indicated primary antibodies (usually 1
μg/ml), followed by horseradishperoxidase-conjugatedAvailable online http://arthritis-research.com/content/8/6/R172
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secondary antibodies. Membranes were thenwashed and vis-
ualized with an enhanced chemiluminescence detectionsys-
tem (Amersham Pharmacia Biotech, now part of GE
Healthcare, Little Chalfont, Buckinghamshire, UK). When nec-
essary, membranes were stripped by incubation in stripping
buffer (62.5 mM Tris-HCl, pH 5.7,100 mM 2-mercaptoethanol,
and 2% SDS) for 30 minutes at 70°C with constant agitation,
washed, and then reprobed with other antibodies asindicated.
Real-time reverse transcription-PCR
Total cellular RNA extraction was performed using the RNA
purification kit from Promega Corporation. The oligonucleotide
primers used for mouse SYN were forward 5-aggcccatgtacct-
ggccatgagg-3 and reverse 5-caggagcgcaggcagctcgtgtg-3.
The QuantiTect SYBR Green PCR kit (Qiagen Inc., Valencia,
CA, USA) was used. Reactions were loaded on 96-well thin-
wall plates and sealed with optical-quality sealing tape. Each
reaction was run on an iCycler iQ Multi-Color Real-Time PCR
detection system (Bio-Rad, Hercules, CA, USA) under the fol-
lowing conditions: 95°C for 15 minutes (94°C for 30 seconds,
55°C for 30 seconds, and 72°C for 30 seconds) for 40 cycles
and 72°C for 3 minutes. Samples were run in triplicate, and rel-
ative copy numbers were determined.
Results
Elevated expression of SYN during CIA in DBA1 mice
Recent studies demonstrated that SYN functions as a rheu-
matoid regulator for the overgrowth of synovial tissues in
patients with RA [11]. To investigate the molecular mecha-
nisms involved in regulating SYN expression during arthritis
development, we compared SYN expression in the synovial
fibroblasts from CIA mice with that from normal mice. Because
the antibodies against SYN are not commercially available, we
first generated anti-SYN polyclonal antibody by immunizing a
fusion protein of GST with the C-terminus of SYN. We
detected both overexpressed and endogenous SYN in HEK
293 cells by using the sera from GST-SYN-immunized mice
(Figure 1a). We therefore used these polyclonal anti-SYN anti-
bodies in this study.
With Western blotting analysis, we found a significantly higher
SYN expression in the synovial fibroblasts from CIA mice than
that from normal controls (Figure 1b). The mean relative den-
sity values (10 × SYN/actin) were 4.8 ± 0.9 for CIA synovial
fibroblasts and 1.1 ± 0.3 for control synovial cells (p < 0.001)
(Figure 1c). These results indicate that SYN expression is
upregulated during CIA.
Figure 1
Increased Synoviolin (SYN) expression in the synovial fibroblasts from collagen-induced arthritis (CIA) mice Increased Synoviolin (SYN) expression in the synovial fibroblasts from collagen-induced arthritis (CIA) mice. (a) Test of the specificity of anti-SYN 
antibody. HEK 293 cells were transfected with (lane 1) or without (lane 2) SYN expression plasmids. Lysates from the transfected cells were ana-
lyzed by SDS-PAGE and Western blotting using sera from the mice immunized with GST (glutathione S-transferase)-SYN fusion protein (top panel). 
The same membrane was reprobed with anti-actin (bottom panel). (b) Analysis of the protein expression of SYN in mouse synovial fibroblasts. 
Mouse synovial fibroblasts were isolated from each of three normal or CIA mice. Cells were lysed and subjected to SDS-PAGE and Western blot-
ting using anti-SYN polyclonal antibodies (top panel). The same membrane was reprobed with anti-actin antibody (bottom panel). (c) Quantification 
of SYN expression. The densities of each band in (b) were analyzed, and the ratio of SYN/(10-1 actin) was used. Error bars represent three different 
CIA or normal mice. Statistic analysis indicates that the expression of SYN is significantly increased (p < 0.001).Arthritis Research & Therapy    Vol 8 No 6    Gao et al.
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Next, we kinetically analyzed the expression of SYN during the
development of CIA. DBA synovial fibroblasts from normal
DBA mice, DBA mice 20 days after the first immunization with
collagen but without any clinical sign of CIA, and DBA mice 10
days after boosted immunization when these mice developed
severe arthritis (score 8 to 12). Surprisingly, the expression of
SYN has been significantly upregulated when the DBA mice
received only the first immunization and did not develop obvi-
ous arthritis. Although statistically not significant (p = 0.06),
boosted immunization further enhanced SYN expression (Fig-
ure 2). These results suggest that upregulation of SYN expres-
sion is involved in the development of CIA in mice.
Induction of SYN expression by IL-1β and TNF-α in 
mouse synovial fibroblasts
The production of proinflammatory cytokines by synovial mac-
rophages and fibroblasts is one reason for synovial cell hyper-
proliferation. We therefore hypothesized that some of these
cytokines may also be responsible for the induction of SYN
expression. To test this hypothesis, we first examined the
effects of proinflammatory cytokines on the expression of SYN
in mouse synovial fibroblasts. Each of 5 × 105 cells was plated
and cultivated in the presence of IL-6, TNF-α, or IL-1β. Forty-
eight hours after the addition of each cytokine, the protein lev-
els of SYN were analyzed. As shown in Figure 3a, TNF-α
slightly induced the protein expression of SYN with a mean
density of 3.1 ± 0.6 compared with 1.1 ± 0.2 of controls from
three independent experiments (p < 0.05 to control), whereas
IL-6 did not affect SYN expression, the mean density of which
was 1.3 ± 0.3 (p = 0.28). The cultivation of synovial fibroblasts
with IL-1β significantly upregulated SYN expression, the mean
density of which was 6.2 ± 1.1 (p < 0.001). These results indi-
cate that both IL-1β and TNF-α induce SYN expression in
mouse synovial fibroblasts.
Figure 2
The expression of Synoviolin (SYN) during collagen-induced arthritis  (CIA) development The expression of Synoviolin (SYN) during collagen-induced arthritis 
(CIA) development. (a) Synovial fibroblasts were isolated from normal 
DBA mice (Normal) and DBA mice 20 days after the first collagen 
immunization (Immunized) or 10 days after the second immunization 
when CIA is developed (CIA). The expression of SYN in those synovial 
fibroblasts was analyzed by Western blotting. (b) The densities of each 
band in (a) were analyzed, and the ratio of SYN/(10-1 actin) was used. 
Error bars represent three different CIA, immunized, or normal mice. 
Statistic analysis indicates that the expression of SYN is significantly 
increased during CIA development.
Figure 3
Induction of Synoviolin (SYN) expression by proinflammatory cytokines Induction of Synoviolin (SYN) expression by proinflammatory cytokines. 
(a) Mouse synovial fibroblasts were starved for 24 hours and then culti-
vated for 48 hours with each proinflammatory cytokine, including 10 
ng/ml of tumor necrosis factor-α (TNF-α), interleukin (IL)-1β, or IL-6. 
The expression of SYN was tested by Western blotting by using anti-
SYN antibody (top panel). As a control, the protein level of actin was 
detected using the same membrane (bottom panel). (b) The total RNA 
from the cultured synovial fibroblasts was isolated and reverse-tran-
scribed into cDNA. The levels of SYN cDNA were analyzed by real-time 
polymerase chain reaction by using SYN-specific primers. Error bars 
represent the results from three independent experiments (mean ± 
standard deviation).Available online http://arthritis-research.com/content/8/6/R172
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To determine whether these cytokines induce SYN expression
at the transcriptional level, total RNA was isolated from these
synovial fibroblasts, reverse-transcribed into cDNA, and exam-
ined by reverse transcription (RT)-PCR using SYN-specific
primers. Real-time RT-PCR revealed that IL-1β induced SYN
expression at the transcriptional level, because the mRNA
level of SYN was upregulated by IL-1β. TNF-α had a weaker
effect on SYN transcription, whereas IL-6 had no effect (Fig-
ure 3b). These results indicate that IL-1β induces SYN expres-
sion at the mRNA level in mouse synovial fibroblasts.
IL-1β and TNF-α induce SYN expression through 
activation of Erk
IL-1β induces the growth of synovial fibroblasts by activating
the MAPK pathways [19-24]. To elucidate the molecular
mechanisms of IL-1β-induced SYN expression, we first tested
the activation of all three MAPK members, including Erk, JNK,
and p38. Because culture of synovial fibroblasts with 10%
fetal bovine serum (FBS) highly activates all these MAPKs, we
first starved the mouse synovial fibroblasts for 24 hours with
media that contain 0.5% FBS, then IL-1β was added. Erk acti-
vation was analyzed with anti-phosphorylated Erk. The phos-
phorylations of c-Jun and ATF2 were used as reporters for the
activation of JNK1 and p38, respectively [19]. The activation
of these MAPKs was not detectable after starvation (Figure
4b–d, lane 1). Cultivation of mouse synovial fibroblasts with IL-
1β activated all three MAPK members, including Erk (Figure
4b, top panel), p38 (Figure 4c, top panel), and JNK1 (Figure
4d, top panel), and IL-1β significantly upregulated SYN
expression (Figure 4a). These results suggest that MAPK
pathways might be involved in IL-1β-induced SYN expression.
To further elucidate which MAPK pathway is involved in regu-
lating IL-1β-induced SYN expression, specific inhibitors of
MAP kinases were used [13-15,25]. Erk inhibitor, PD98059,
specifically inhibited Erk phosphorylation without affecting the
activation of either JNK or p38 (Figure 4b, lane 3). In the pres-
ence of this inhibitor, SYN expression was reduced to a level
that is comparable with non-treated controls (Figure 4a, top
panel, lane 3). p38 inhibitor, SB202190, which specifically
inhibited ATF2 phosphorylation without affecting Erk and
JNK1 activation, had a very mild inhibitory effect on SYN
expression (Figure 4c, lane 4). The specific inhibitor of JNK,
SP600125, which specifically inhibited c-Jun phosphorylation,
had no effects on IL-1β-induced SYN expression (Figure 4d,
lane 5). Similarly, the Erk inhibitor also inhibited TNF-α-
induced SYN expression (Figure 4e). Both IL-1β and TNF-α
are also strong activators of the NF-κB pathway [24]. We
therefore tested whether NF-κB activation is also involved in
the induction of SYN expression in mouse synovial fibroblasts.
The NF-κB-specific inhibitor, SN50, strongly inhibited both IL-
1β and TNF-α-induced NF-κB reporter activities (Figure 4g)
but not the SYN protein expression (Figure 4f). These findings
collectively indicate that IL-1β and TNF-α enhance SYN
expression through the activation of Erk, but not the p38, JNK,
or NF-κB pathways.
Transcription factor ETS1 is involved in IL-1β-induced 
SYN expression
ETS1 is a transcription factor, the expression of which is
increased in synovial fibroblasts from patients with RA [27].
Recently, the ETS binding site (EBS), termed EBS-1, from
position -76 to -69 of the proximal promoter, was identified as
being responsible for SYN expression [28]. Interestingly, we
found that overexpression of ETS1 further enhanced IL-1β-
induced SYN expression in a dose-dependent manner (Figure
5a, lanes 3 and 4; Figure 5b). To further confirm the involve-
ment of ETS1 in SYN expression, we generated a C-terminal
truncate mutation of ETS1, which has been shown to be a
dominant negative mutant of ETS1 (ETS1-DN) [29]. As shown
in Figure 4a (lanes 5 and 6), ETS1-DN dramatically blocked
SYN expression induced by IL-1β in mouse synovial fibrob-
lasts. These results indicate that the transcription factor is
involved in regulating IL-1β-induced SYN expression in mouse
synovial fibroblasts.
Activation of Erk and ETS1 is involved in the overgrowth 
of synovial fibroblasts from CIA mice
We next tested whether the activation of Erk is enhanced in
the synovial fibroblasts from CIA mice, in which SYN expres-
sion is increased. As expected, both Erk1 activation and Erk2
activation are slightly increased in CIA synovial fibroblasts
compared with those from normal DBA1 mice (Figure 6a).
Interestingly, in treatment with the Erk-specific inhibitor, the
expression of SYN was reduced to comparable levels
between normal and CIA synovial fibroblasts. These results
suggest that Erk activation is involved in upregulating SYN
expression  in vivo during CIA development. It has been
reported that the expression of ETS1 protein is increased in
the synovial fibroblasts from patients with RA [27]. We com-
pared the activation and protein expression of ETS1 in the syn-
ovial fibroblasts from CIA mice with those from normal DBA1
mice. As shown in Figure 6a, we found that the activation of
ETS1 but not its protein expression was increased in CIA syn-
ovial fibroblasts. These results suggest that the activation of
both Erk and ETS1 is involved in regulating the expression of
SYN in mouse synovial fibroblasts during CIA.
Based on previous studies that have suggested that Erk may
activate ETS1 transcription activity [30] together with our find-
ings that Erk and ETS1 are involved in IL-1β-induced SYN
expression, we proposed that IL-1β induces SYN expression
in mouse synovial fibroblasts via the Erk-ETS1 pathway. To
support this hypothesis, we found that inhibition of Erk activa-
tion by Erk-specific inhibitor blocked ETS1 phosphorylation
(Figure 6a). Moreover, Erk inhibitor suppressed the cell growth
of mouse synovial fibroblasts, and the synovial fibroblasts from
CIA mice were more sensitive to Erk inhibition (Figure 6b).
Treatment of these cells with the Erk inhibitor did notArthritis Research & Therapy    Vol 8 No 6    Gao et al.
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significantly arrest the cell cycle of these synovial fibroblasts
from either normal DBA or CIA mice (Figure 6c). These find-
ings suggest that the activation of Erk and ETS1 is involved in
the overgrowth of mouse synovial fibroblasts during CIA.
Based on these findings, we collectively concluded that the
Erk-ETS1 pathway is involved in SYN expression in mouse
synovial fibroblasts induced by IL-1β and TNF-α.
Discussion
Proinflammatory cytokines, particularly IL-1β and TNF-α, can
induce the cell proliferation of synovial fibroblasts both in vitro
and in vivo [31,32]. The molecular mechanisms of proinflam-
matory cytokine-induced cell growth of synovial tissues have
been extensively investigated, although there still is room for
debate [33]. IL-1β and TNF-α are key activators of the many
transcription factors, including activator protein-1 (AP-1), Egr-
1 (early growth response-1), and NF-κB, in synovial fibrob-
lasts. Activation of the NF-κB/Rel transcription family and AP-
1 complexes, composed of members of the Jun and Fos fami-
lies, contributes to the hyperproliferation of fibroblast-like syn-
oviocytes [34]. We found that IL-1β induces the proliferation
of synovial fibroblasts by upregulating SYN expression. These
findings provide a new mechanism for IL-1β in synovitis during
RA development.
Figure 4
Interleukin (IL)-1β and tumor necrosis factor-α (TNF-α) induce Synoviolin (SYN) expression via the Erk pathway Interleukin (IL)-1β and tumor necrosis factor-α (TNF-α) induce Synoviolin (SYN) expression via the Erk pathway. (a) Synovial fibroblasts were par-
tially starved for 24 hours by cultivation of these cells with media that contain 0.5% fetal bovine serum and then cultured with 10 ng/ml of IL-1β. Cells 
were also treated with each of the MAPK inhibitors. The concentrations of each inhibitor used were as follows: Erk inhibitor PD98059, 20 μM; JNK 
inhibitor SP600125, 10 μM; p38 inhibitor SB202190, 10 μM; and NF-κB inhibitor SN50, 20 μM. The expression of SYN was examined by Western 
blotting (top panel). The protein level of actin was reprobed as a control (bottom panel). (b) The activation of Erk was analyzed by anti-p-Erk antibody 
(top panel). The same membrane was reprobed by anti-Erk antibody (bottom panel). (c) p38 activation was analyzed by anti-p-ATF2 antibody (top 
panel). The same membrane was reprobed by anti-ATF2 antibody (bottom panel). (d) JNK1 activation was analyzed with anti-phospho-Jun antibody 
(top panels). The total protein levels of c-Jun were examined using anti-Jun (bottom panels). (e) Mouse synovial fibroblasts were starved for 24 hours 
and then cultured with 10 ng/ml of TNF-α without or with Erk inhibitor. The expression of SYN was analyzed by Western blotting (top panel). The 
activation of Erk was determined by anti-phosphorylated Erk antibody (middle panel). The protein level of Erk was analyzed by anti-Erk antibody (bot-
tom panel). (f) The effect of NF-κB inhibitor on SYN expression. Mouse synovial fibroblasts were transfected with NF-κB-luc reporter, which con-
tains firefly luciferase gene under control of NF-κB. The control plasmid pRL-TK encoding renillar luciferase was also included to correct transfection 
efficiency. Transfected cells were starved and then cultivated in the presence of 10 ng/ml of IL-1β or TNF-α without or with SN50 for 24 hours. The 
expression of SYN in these cells was analyzed by Western blotting (top panel), and the same membrane was reprobed with anti-actin (middle panel). 
(g) Parallel prepared cell lysates from (f) were used for testing the NF-κB-driven luciferase activity (bottom panel). Error bars represent three differ-
ent experiments (mean ± standard deviation). Erk, extracellular signal-regulated kinase; JNK, c-Jun N-terminal kinase; MAPK, mitogen-activated pro-
tein kinase; NF-κB, nuclear factor-kappa B.Available online http://arthritis-research.com/content/8/6/R172
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MAPKs are especially important in synovitis because they con-
trol the proliferation of synovial cells in the rheumatoid joint and
induce the production of MMPs and cytokines that participate
in the rheumatoid process [33,35]. The involvement of all three
MAPK family members, JNK, Erk, and p38, in RA has been
indicated by the fact that their activation is increased in rheu-
matoid synovial cells. They have also been implicated in the
pathogenesis of RA [33]. The binding of IL-1β to its receptor
expressed on the surface of synovial fibroblasts activates all
three MAPK members, as demonstrated in our study and pre-
vious reports [33]. Intriguingly, only Erk activation is involved in
SYN transcription, as indicated by the finding that the specific
inhibitors against Erk, but not JNK and p38, block SYN expres-
sion. It has been demonstrated that Erk activation is highly
increased in the synovial fibroblasts from patients with RA.
Consistent with this, we found that the activation of Erk is sig-
nificantly upregulated in mouse synovial fibroblasts from CIA
mice compared with that from normal DBA1. Interestingly, the
CIA synovial fibroblasts are more sensitive to Erk inhibitor-
mediated cell growth inhibition. Therefore, Erk inhibitors could
be potential candidates for RA treatment.
Recently, EBS-1 was identified as a crucial site for the expres-
sion of SYN [28]. EBS-1 is a binding site for ETS family
transcription factors, including ETS1/2, GABP (growth-asso-
ciated binding protein)-α/β, and Sp-1 [36]. Our findings that
ETS1 expression increases SYN transcription and that ETS1-
DN blocks SYN expression (Figure 4) confirm that the EBS-1
binding site is the promoter region for IL-1β-induced SYN
expression. ETS1 is activated by Erk-mediated phosphoryla-
tion [37]. Therefore, inhibition of Erk activation by specific
inhibitors blocks SYN transcription (Figure 3). Overexpression
of ETS1 family transcription factors has been observed in RA
synovial membranes [19,27]. However, we found that the acti-
vation of ETS1 but not its protein expression is upregulated in
the synovial fibroblasts from CIA mice. The elevated ETS1
activation is possibly a direct consequence of Erk activation,
because inhibition of Erk activation blocks ETS1
phosphorylation.
As an E3 ubiquitin ligase on the ER membrane, SYN functions
as an ER-associated degradation system in both yeast and
mammals [8,9]. The biological functions of SYN were analyzed
in SYN transgenic mice and heterozygous knockout mice
because the homozygous mice are embryonic-lethal [11].
Interestingly, the expression level of SYN correlates signifi-
cantly with the onset of arthropathy: Increased SYN expres-
sion causes synovium overgrowth and spontaneous
arthropathy, whereas reduced SYN expression (heterozygous
mutant mice) is associated with resistance to CIA [11]. Our
finding that the suppression of SYN inhibits IL-1β-induced
synovial fibroblast proliferation provides a direct rationale for
SYN as a potential target for the treatment of RA. It will be
extremely interesting to investigate the effects of gene thera-
peutic delivery of dominant-negative SYN or its siRNA (small
interfering RNA) on the development of arthritis in animals
such as DBA mice with CIA.
Conclusion
This study demonstrated that the proinflammatory cytokines
IL-1β and TNF-α induce synovial fibroblast growth by
upregulating the expression of an E3 ubiquitin ligase, SYN. At
the molecular level, activation of MAPK Erk and transcription
factor ETS1 is required for SYN expression. Based on our
findings and the fact that synovial fibroblasts are among the
major resources for IL-1β and TNF-α in the rheumatoid joints
Figure 5
ETS1 is involved in interleukin-1β(IL-1β)-induced Synoviolin (SYN)  expression ETS1 is involved in interleukin-1β(IL-1β)-induced Synoviolin (SYN) 
expression. (a) ETS1 or ETS1-DN expression plasmids were trans-
fected into mouse synovial fibroblasts. Cells were then cultured in 
medium containing 10 ng/ml of IL-1β for 48 hours. The expression of 
SYN was detected by Western blotting (top panel). The expression of 
ETS1 and its mutant was detected with anti-ETS1 antibody (middle 
panel). The same membrane was stripped and reblotted with anti-actin 
antibody (bottom panel).(b) The expression level of SYN was quanti-
fied. Error bars represent three independent experiments (mean ± 
standard deviation). ETS1-DN, dominant negative mutant of ETS1.Arthritis Research & Therapy    Vol 8 No 6    Gao et al.
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[31], we proposed a positive feedback model for SYN in RA
development (Additional file 2). According to this model, IL-1β
induces SYN transcription, SYN enhances IL-1β-induced syn-
ovial fibroblast proliferation, and the massive growth of syno-
vial fibroblasts produces more IL-1β for the induction of SYN
expression. This positive feedback process may be critical in
RA development. Molecules in this signal pathway can there-
fore be potential targets against RA.
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16 hours. 3H-tymidine incorporation was analyzed as described previously [18]. Error bars represent three independent experiments (mean ± stand-
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and fixed in cold methanol and then stained with propidium iodide (PI) in the presence of RNase. PI-stained cells were washed once with phosphate-
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